Acquisition includes manufacturing assets from Nucryst's Fort Saskatchewan, Canada operations and the intellectual property estate

The Advanced Wound Management division of Smith & Nephew has reported that its affiliates have completed the acquisition of all the assets of Nucryst Pharmaceuticals (Nucryst). The acquisition includes the manufacturing assets from Nucryst’s Fort Saskatchewan, Canada operations and the intellectual property estate.

Since 2001, Smith & Nephew has held exclusive license for the sale of the Acticoat dressing portfolio, manufactured at the Ft. Saskatchewan site.

This acquisition gives Advanced Wound Management full control over all the intellectual property rights, manufacturing and assets relating to the nanocrystalline silver technology that is incorporated in Acticoat, said Smith & Nephew.

Roger Teasdale, president of Advanced Wound Management, said: “The Acticoat dressings are the only products on the market using the proprietary antimicrobial nanocrystalline silver technology known as Silcryst. Acquiring this technology and the manufacturing capabilities behind it underlines our commitment to bring clinicians and patients the most advanced solutions for their wound care needs.”